Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

DiCE Molecules Forges Multi-Year Research Deal with Genentech

A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. The Bay Area company inked a multi-year collaborative agreement with Genentech to discover new small molecules.

Read More »

Shire’s Hunter Syndrome Treatment Fails Study Goals

Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.

Read More »

FDA approves Spark Therapeutics’ gene therapy

The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.

Read More »

Chocolate makers innovate to entice health-conscious consumers

The world’s largest chocolate makers are looking for ways to keep increasingly health-conscious consumers coming back for more.

Read More »

Humana, private equity firms buy Kindred Healthcare for $810 million

U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.

Read More »

Dr. Reddy’s resolves U.S. probe over drug packagingp

Dr. Reddy’s Laboratories will pay $5 million to resolve claims that the Indian company sold prescription drugs in the U.S. in packaging not tested for child safety.

Read More »

Aerie’s glaucoma treatment gets early FDA approval

The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.

Read More »

Intouch Solutions Promotes Five Chicago Employees

Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced the promotion of five employees in its Chicago office.

Read More »

Novartis Buys Rare Drug Voucher From Ultragenyx

Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc. The PRV is for rare pediatric diseases.

Read More »

Boehringer Inks Deal With GlaxoSmithKline Spinout

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom